ArticleEuropean journal of epidemiology2026
Survival trends and cure rates of hematological neoplasms in the Spanish pediatric population.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematological neoplasms (HN) were the first cause of death in children aged 5-9 years in Spain. The aim of this registry-based study is to provide a detailed overview of the survival of HN in the Spanish pediatric population. All pediatric HN cases included were classified according to the International Classification for Childhood Cancer. Flexible parametric models were used to estimate survival probabilities and long-term survival projections. Survival trends were evaluated with the annual average change in survival (AAC_S). Latent cure models were used to estimate cure fractions (CF). A total of 4706 cases of HN were diagnosed in Spain during 2000-2016, for which 2850 (60.6%) were boys. Leukemias and lymphoid leukemias (LL) were the most common type and subtype of HN in children. An overall 5- year survival of 84.3% [95% confidence intervals (CI): 83.3, 85.3] was observed for HNs. Children aged < 1 year with acute myeloid leukemia (AML) or myelodysplastic syndrome had the worst prognosis. An improvement over time was observed for all HN with an AAC_S of 0.71% [95% CI 0.50, 0.91], of which AML and Burkitt lymphomas displayed the greatest improvements. HNs revealed CF of 83.8% [95% CI 82.4, 85.3], with the highest CF being nearly 100% in Hodgkin lymphomas. Larger population coverage with updated data have aligned the Spanish results to those observed in other European countries. Continuous refinements in treatments, patient care and better diagnostic methods have revealed the highest survival improvements for HN subtypes with bad prognosis in children.
Indexed as
Identifiers
40991150What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.